Back Hepatitis C

Hepatitis C

EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower

A dual oral regimen containing the hepatitis C polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response among people with HCV genotype 2, while those with genotype 3 did not fare as well, researchers reported this week at the 48th EASL International Liver Congress (EASL 2013) in Amsterdam.alt

EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1

A 4-drug combination of direct-acting antivirals developed by AbbVie cured genotype 1 hepatitis C virus (HCV) infection in over 90% of participants in the AVIATOR study, without the need for the use of interferon, researchers reported at the 48th International Liver Congress (EASL 2013) on Thursday in Amsterdam. A 12-week treatment course will go forward to Phase 3 studies.


CROI 2013: Telaprevir Triple Therapy Improves HCV Response for Black Null Responders

Adding the HCV protease inhibitor telaprevir (Incivek) to pegylated interferon and ribavirin increased end-of-treatment response rates for difficult-to-treat patients including African-Americans who previously did not respond to interferon, according to study results presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)in Atlanta.


Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir

Janssen has submitted requests for approval in the U.S. and Europe for its investigational HCV protease inhibitor simeprevir (formerly TMC435) as an addition to interferon-based therapy for people with genotype 1 or 4 chronic hepatitis C virus infection. The company announced that it filed a New Drug Application with the U.S. Food and Drug Administration (FDA) on March 28, followed by a Marketing Authorisation Application to the European Medicines Agency (EMA) on April 24.


CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]

The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.alt

[Produced in collaboration with IFARA]

In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of about implications of new therapies for hepatitis C patients and providers.

Daclatasvir + Asunaprevir Works Well for Patients Who Cannot Use Interferon

A dual combination of the HCV NS5A inhibitor daclatasvir (formerly BMS-790052) and HCV protease inhibitor asunaprevir (formerly BMS-650032) cured three-quarters of Japanese patients unable to take interferon, including 90% of prior null responders, according to a study described in the April 2013 Journal of Hepatology.


CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection

New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.alt

Gilead Submits New Hepatitis C Drug Sofosbuvir for FDA Approval

Gilead Sciences this week submitted a New Drug Application (NDA) requesting approval of its investigational HCV polymerase inhibitor sofosbuvir (formerly GS-7977) as part of interferon-free therapy with ribavirin for people with HCV genotypes 2/3 or a shorter interferon-based regimen for those with harder-to-treat genotypes.


CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients

A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.alt